GoodRx vs IVY RX: Prices, Programs & Reviews (2026)
Side-by-side comparison updated for 2026. ClearScores, pricing, medications, and ratings compared.
Quick Verdict
GoodRx has the higher ClearScore (72 vs 69)
GoodRx is more affordable ($119/mo vs $197/mo)
GoodRx has higher ratings (4/5 vs 3.8/5)
GoodRx scores better on value (4.4/5 vs 4.3/5)
GoodRx
$119/mo
starting price
Trusted prescription savings brand now offering GLP-1 telemedicine with $199 introductory Wegovy/Ozempic pricing.
IVY RX
$197/mo
starting price
Flat-rate GLP-1 pricing that does not increase with dose. Semaglutide from $175/mo. Pharmacist-founded, 200K+ members.
GoodRx vs IVY RX: Full Comparison
| GoodRx | IVY RX | |
|---|---|---|
| ClearScore | 72/100 ✓ | 69/100 |
| Overall Rating | 4/5 ✓ | 3.8/5 |
| Review Count | 89 ✓ | 67 |
| Starting Price | $119/mo ✓ | $197/mo |
| Medications | Branded Semaglutide, Branded Tirzepatide | Compounded Semaglutide, Compounded Tirzepatide |
| Telehealth | Yes | Yes |
| Insurance | Not accepted | Not accepted |
| HSA/FSA | Accepted | Accepted |
| Founded | 2011 | 2023 |
| States Served | All 50 states | All 50 states |
Programs & Pricing
GoodRx Programs
GoodRx for Weight Loss
$119/mo + medication
Medications: Branded Semaglutide, Branded Tirzepatide
- Clinician Consultations
- Ongoing Support
- Prescription Savings
- Flexible Fulfillment
IVY RX Programs
Semaglutide Program
$175-197/mo
Medications: Compounded Semaglutide
- Medication
- Consultation
- Shipping
- Supplies
Tirzepatide Program
$275-297/mo
Medications: Compounded Tirzepatide
- Medication
- Consultation
- Shipping
- Supplies
Ratings Breakdown
| Category | GoodRx | IVY RX |
|---|---|---|
| Overall | | |
| Value | | |
| Ease of Use | | |
| Support | | |
| Medication Quality | | |
| Results | | |
The Bottom Line
GoodRx edges out IVY RX with a ClearScore of 72 vs 69. GoodRx is more affordable starting at $119/mo compared to $197/mo. For customer support, GoodRx rates higher (3.8/5). The best choice depends on your priorities, medication preferences, and budget.